Evidence map›Paper›PMID 32936372›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2021

[

Antonio Cabrera Villegas, Leonardo G Romero Robles, Xavier L E Boulvard Chollet, M Clara Albornoz Almada, María Mangas Losada, Puy Garrastachu, Francisco M Cañete Sánchez, Rafael Ramírez Lasanta, Roberto C Delgado Bolton

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05009563 (Evaluation of COVID-19 by Whole-body FDG-PET/CT), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05009563 naunknown statusnot on this map

Evaluation of COVID-19 by Whole-body FDG-PET/CT

TypeinterventionalSponsorSemmelweis University Heart and Vascular CenterRan2021 to 2022Enrolled50ConditionsCoronavirus InfectionArmsFDG-PET/CT
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Contribution ofCurrent issues in molecular biology · 2025
    Review
  2. Article
  3. Review
  4. Nuclear Medicine Departments in the Era of COVID-19.Seminars in nuclear medicine · 2022
    Review
  5. Article
  6. Role of 2-[Pharmaceuticals (Basel, Switzerland) · 2020
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Antonio Cabrera VillegasDepartment of Diagnostic Imaging (Radiology) and Nuclear Medicine, University Hospital San Pedro and Centre for Biomedical Research of La Rioja (CIBIR), C/ Piqueras 98, 26006, Logroño, La Rioja, Spain.
Leonardo G Romero RoblesDepartment of Diagnostic Imaging (Radiology) and Nuclear Medicine, University Hospital San Pedro and Centre for Biomedical Research of La Rioja (CIBIR), C/ Piqueras 98, 26006, Logroño, La Rioja, Spain.
Xavier L E Boulvard CholletDepartment of Diagnostic Imaging (Radiology) and Nuclear Medicine, University Hospital San Pedro and Centre for Biomedical Research of La Rioja (CIBIR), C/ Piqueras 98, 26006, Logroño, La Rioja, Spain.
M Clara Albornoz AlmadaDepartment of Diagnostic Imaging (Radiology) and Nuclear Medicine, University Hospital San Pedro and Centre for Biomedical Research of La Rioja (CIBIR), C/ Piqueras 98, 26006, Logroño, La Rioja, Spain.
María Mangas LosadaDepartment of Diagnostic Imaging (Radiology) and Nuclear Medicine, University Hospital San Pedro and Centre for Biomedical Research of La Rioja (CIBIR), C/ Piqueras 98, 26006, Logroño, La Rioja, Spain.
Puy GarrastachuDepartment of Diagnostic Imaging (Radiology) and Nuclear Medicine, University Hospital San Pedro and Centre for Biomedical Research of La Rioja (CIBIR), C/ Piqueras 98, 26006, Logroño, La Rioja, Spain.
Francisco M Cañete SánchezDepartment of Diagnostic Imaging (Radiology) and Nuclear Medicine, University Hospital San Pedro and Centre for Biomedical Research of La Rioja (CIBIR), C/ Piqueras 98, 26006, Logroño, La Rioja, Spain.
Rafael Ramírez LasantaDepartment of Diagnostic Imaging (Radiology) and Nuclear Medicine, University Hospital San Pedro and Centre for Biomedical Research of La Rioja (CIBIR), C/ Piqueras 98, 26006, Logroño, La Rioja, Spain.
Roberto C Delgado BoltonDepartment of Diagnostic Imaging (Radiology) and Nuclear Medicine, University Hospital San Pedro and Centre for Biomedical Research of La Rioja (CIBIR), C/ Piqueras 98, 26006, Logroño, La Rioja, Spain. rbiolton@gmail.com.ORCID https://orcid.org/0000-0002-8071-6513
Hospital San Pedro · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSpain has been one of the most affected countries by the COVID-19 pandemic, being among the countries with worse numbers, including the death rate. However, most patients are asymptomatic, although they are very contagious. The objective of this study was to investigate the incidence in oncological patients infected with SARS-CoV-2 that are asymptomatic for COVID-19 and at home and that undergo PET/CT for oncologic indications, nonrelated to COVID-19, finding in the PET/CT lung alterations that are suggestive of SARS-CoV-2 infection.

methodsDuring the period of maximum incidence of the global pandemic in one of the most affected regions of Spain, there were 145 patients that met inclusion and exclusion criteria and were included in the study. Imaging findings previously described such as ground-glass opacities with low [

resultsSuspicious lung imaging findings were present in 7 of 145 patients (4.8%). Five of these 7 patients were confirmed as presenting SARS-CoV-2 infection, this is, COVID-19. In the remaining two, it was not possible to confirm the presence of COVID-19 with RT-PCR, although in one of them, PET/CT allowed an early diagnosis of a lung infection related to a bacterial pneumonic infection that was promptly and adequately treated with antibiotics.

conclusionThese results confirm that the prevalence of SARS-CoV-2 infection is higher than suspected and that there are asymptomatic patients that are attending imaging departments to be explored for their baseline oncologic processes. In these patients, PET/CT allows an early diagnosis of COVID-19.

Indexed as

Asymptomatic InfectionsCOVID-19FemaleFluorodeoxyglucose F18HumansMaleNeoplasmsPandemicsPositron Emission Tomography Computed TomographySARS-CoV-2SpainFluorodeoxyglucose F18CancerCoronavirusCOVID-19FDG PET/CTOncologic indicationsRT-PCR

Identifiers

PMID32936372
PMCPMC7492231
OpenAlexW3086775363

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.